BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Algeta Schedules Fourth Quarter and Full Year 2012 Results Presentation, Webcast and Conference Call


2/19/2013 9:06:07 AM

OSLO, NORWAY--(Marketwire - February 18, 2013) - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, will announce its fourth quarter and full year 2012 results on Thursday, 28 February 2013. A presentation by Algeta's senior management team to investors, analysts and the press will take place in Oslo at 10:00 CET. The presentation will also be webcast live and can be accessed through www.algeta.com where questions can also be submitted during the presentation.

The presentation will take place at 10:00 CET at:

Shippingklubben

Haakon VIIs gate 1

0161 Oslo

Norway.

Algeta's senior management will also host an international conference call at 14:30 CET/08:30 Eastern Time (US) (details below).

To participate in the conference call, please dial the appropriate number below five minutes prior to the call:

US: +1 877 423 0830

UK: +44 20 7153 9154

Norway: +47 21 06 61 13

Sweden: +46 8-506 443 86

Denmark: +45 32 71 42 62

Switzerland: +41 44 580 65 22

Participant pin code: 434633#

To access the replay, please dial:

US: +1 877 679 2989

UK: +44 20 3364 5196

Norway: +47 23 50 02 03

Sweden: +46 8-505 564 73

Conference reference: 345360#

A replay version of the conference call will also be available at www.algeta.com.

The results report and the presentation will be available at www.algeta.com in the Investors section from 07:00 CET.

About Algeta

Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com.

Press release:

http://hugin.info/134655/R/1678620/547936.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Algeta ASA via Thomson Reuters ONE

[HUG#1678620]


For further information, please contact:

Mike Booth / Renate Birkeli
+47 23 00 67 32

Communications & Corporate Affairs
Email Contact

Media enquiries:
Mark Swallow
+44 207 638 9571

Citigate Dewe Rogerson
Email Contact

Knut Ekern
+47 22 04 82 00

Gambit Hill & Knowlton
Email Contact

Kari Watson
+1 781 235 3060

MacDougall Biomedical Communications
Email Contact

US investor enquiries:

Tricia Swanson
+1 646 378 2953

The Trout Group
Email Contact



Read at BioSpace.com

Algeta AS
Algeta
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES